Status:

COMPLETED

Nicotinic Receptors and Schizophrenia

Lead Sponsor:

University of Colorado, Denver

Collaborating Sponsors:

National Institute of Mental Health (NIMH)

Conditions:

Schizophrenia

Schizoaffective Disorder

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

The investigators hypothesize that sustained-release DMXB-A-SR (3-2,4 dimethoxybenzylidene anabaseine sustained release) will provide clinical improvement in cognition in patients with schizophrenia w...

Detailed Description

Patients with schizophrenia will be screened then enrolled for one week placebo trial in addition to their existing antipsychotic medication. If pill compliance is greater than 80%, then they will rec...

Eligibility Criteria

Inclusion

  • Subjects will be selected to be 18 to 65 years old and in good general health.
  • Subjects who fulfill Diagnostic and Statistical Manual -IV-Text Revision (DSM-IV-TR) criteria for schizophrenia or schizoaffective disorder.
  • Smokers will smoke at least 20 cigarettes per day.
  • Non-smokers will also be enrolled.
  • Subjects will have normal:
  • vital signs,
  • hematology,
  • serum chemistries,
  • EKG, and
  • urinalysis with a negative drug screen before entry into the study.
  • Subjects will be fluent in English.
  • Smoking subjects will be interested in stopping smoking in the near future and not interested in nicotine replacement therapy.

Exclusion

  • Subjects with histories of:
  • neurological illness,
  • liver disease,
  • severe hypertension (cut-off blood pressure 160/100) or
  • cardiac disease, or
  • renal failure (cut-off creatinine above 1.4).
  • Subjects who currently meet DSM-IV-TR criteria for substance dependence other than nicotine, cannabis, or alcohol will be excluded.
  • Women who are capable of pregnancy and not on acceptable forms of birth control will be excluded.
  • Subjects being treated with Clozapine will be excluded.

Key Trial Info

Start Date :

July 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2015

Estimated Enrollment :

97 Patients enrolled

Trial Details

Trial ID

NCT01400477

Start Date

July 1 2011

End Date

June 1 2015

Last Update

May 7 2019

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

UColorado Denver

Aurora, Colorado, United States, 80045

2

University of Colorado-Anschutz Medical Campus, Department of Psychiatry

Aurora, Colorado, United States, 80045